ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy

Liu, Weiwei; Liu, Chaoqun; Wang, Hui; Xu, Lijun; Zhou, Jueyu; Li, Sihua; Cheng, Yu; Zhou, Rui*; Zhao, Liang*广州医学院; 南方医科大学
Computational and Structural Biotechnology Journal2022DOI: 10.1016/j.csbj.2022.09.017
5被引12阅读
引用收藏
分享

摘要

Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs have been successfully applied in the treatment of different cancers, the low effectiveness rate has dramati-cally restrained the clinical application of ICI treatment. N6-methyladenosine (m6A) modification is the most common RNA methylation. Recent studies have pointed out that m6A epigenetic modification could improve the efficacy of ICI blockade treatment. Here, we briefly summarize the relevant mecha-nisms of tumour immunity, the clinical application of ICIs, the resistance to ICI treatment in cancers, and the m6A epigenetic modification and how it regulates the response to ICI treatment. We attempted to provide a potential strategy for cancer therapy by targeting m6A modification combined with ICI blockade treatment. CO 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).

学科与关键词

关键词
ICBM6A modificationCancer immunotherapym6A regulators
相关
加载中…
  • Targeting RNA N6-methyladenosine modification: a precise weapon in overcoming tumor immune escape
    Li, Wei; Hao, Yi; Zhang, Xingda; Xu, Shouping*; Pang, Da*Molecular Cancer, 2022, 21(1): 176.被引 12
  • N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma
    Wang, Gaofeng; Zeng, Dongqiang; Sweren, Evan; Miao, Yong; Chen, Ruosi; Chen, Junjun; Wang, Jin; Liao, Wangjun; Hu, Zhiqi; Kang, Sewon; Garza, Luis A.*Journal of Investigative Dermatology, 2023, 143(8).被引 1
  • N6-methyladenosine RNA modifications: a potential therapeutic target for AML
    Hu, Rong; Liao, Peiyun; Xu, Binyan; Qiu, Yingqi; Zhang, Honghao; Li, Yuhua*Annals of Hematology, 2023.
查看全部 →

发表信息

论文状态
公开发表
期刊
Computational and Structural Biotechnology Journal
发表日期
2022
卷期
第 20 卷
页码
5150-5161
DOI
10.1016/j.csbj.2022.09.017
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foun-dation of China; Natural Science Foundation of Guangdong Province; Beijing Xisike Clinical Oncology Research Foundation; [81972813]; [81902946]; [82173172]; [2021B1515120001]; [2021A1515111190]; [2020A1515011389]; [Y-Roche2019/2-0025]

作者

  • L

    Liu, Weiwei (第一作者)

    southern med univ

  • L

    Liu, Chaoqun

    southern med univ

查看全部 9 位作者收起作者
  • W

    Wang, Hui

    guangzhou med univ

  • X

    Xu, Lijun

    southern med univ

  • Z

    Zhou, Jueyu

    southern med univ

  • L

    Li, Sihua

    southern med univ

  • C

    Cheng, Yu

    southern med univ

  • Z

    Zhou, Rui (通讯)

    southern med univ

  • Z

    Zhao, Liang (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417